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Abstract
Enterovirus 71 (EV71) infection is more likely to induce severe complications and mortality than other enteroviruses.
Methods for detection of IgM antibody against EV71 had been established for years, however, the performance of the
methods in the very early diagnosis of EV71 infection had not been fully evaluated, which is especially meaningful because
of the short incubation period of EV71 infection. In this report, the performance of an IgM anti-EV71 assay was evaluated
using acute sera collected from 165 EV71 infected patients, 165 patients infected with other enteroviruses, and more than
2,000 sera from healthy children or children with other infected diseases. The results showed a 90% sensitivity in 20 patients
who were in their first illness day, and similar sensitivity remained till 4 days after onset. After then the sensitivity increased
to 95% to 100% for more than one month. The specificity of the assay in non-HFMD children is 99.1% (95% CI: 98.6–99.4),
similar as the 99.9% specificity in healthy adults. The cross-reaction rate in patients infected with other non-EV71
enteroviruses was 11.4%. In conclusion, the data here presented show that the detection of IgM anti-EV71 by ELISA affords a
reliable, convenient, and prompt diagnosis of EV71 infection.
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Introduction
Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) are the
principal pathogens of hand foot and mouth disease (HFMD).
EV71 is of special concern because it is more likely to induce
severe complications and mortality than other enteroviruses, and
has become endemic in Southeast Asia for tens of years [1,2]. It
has caused several wide spread epidemics in this region since 1997
and is expected to continue to do so in the future [3–6]. There is
no effective anti-virus treatment for EV71 and control depends on
prompt diagnosis and timely implementation of appropriate
measures to contain the spread of the infection [7,8].
Laboratory diagnosis of EV71 relies mainly on detection of the
viral genome by reverse transcription polymerase chain reaction or
on virus isolation techniques [9–13]. However, these methods
were unaffordable in most community clinics in developing
countries in which most epidemics occurred. Tsao et al. (2002)
showed and confirmed later by Wang et al. (2004) that IgM anti-
EV71 was detectible in patients [14,15]. However, due to the very
limited number of evaluated clinical samples in these studies, the
diagnosis accuracy of IgM anti-EV71 test had not been well
determined [16]. The aim of this study was to assess the
performance of detecting IgM anti-EV71 for early diagnosis of
patients with HFMD.
Materials and Methods
Ethic Statement
Written informed consent was obtained from each subject.
Independent Ethics Committee approval was obtained from the
Ethics Committee of the National Institute of Diagnostics and
Vaccine Development in infectious diseases.
Study design
The sensitivity of the IgM anti-EV71 assay was evaluated in
HFMD patients who were confirmed to be recently EV71
infection, and was classified by the days apart from the onset.
The specificity of the assay was evaluated in children patients with
confirming diagnosis of other respiratory diseases. The cross-
reactivity of the assay was evaluated in HFMD patients infected by
other enteroviruses.
Serum samples
A total of 376 serum samples were collected from HFMD
patients, herpangina, aseptic meningitis, or encephalitis between
March and September 2008. Of these samples, 221 were collected
from 165 EV71-infected patients with the mean age of 2.662.1,
155 were from CA16–infected patients with the mean age of
2.762.5. The infection of EV71 or CA16 among these patients
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11388was determined by detection of the viral RNA by reverse
transcript PCR. Twelve serum samples collected from patients
infected by other enteroviruses (4 coxsackievirus A2, 1 coxsack-
ievirus A4, 1 coxsackievirus B3, 2 coxsackievirus B4, 2
coxsackievirus B5, and 2 echovirus 6) were gifts from Dr. P. J.
Chen of National Taiwan University, which were determined by
virus isolation.
Control samples for this study included three groups. The first
group included 128 sera from children patients with the following
clinical features: Pneumonia (83 cases), Bronchitis (18), acute
upper respiratory infections (15), and Influenza (12). The second
group included 1907 stored sera from healthy children who
received health examinations in with the mean age of 2.162.7.
The third group included 807 sera from healthy adult blood
donors. The EV71 neutralizing antibody titers of all control
samples were less than 1:100. Twenty serum samples positive with
rheumatoid factor were also used to evaluate the possible
disturbance to IgM testing. All serum samples were kept in
aliquots at 220uC until use.
Viral RNA extraction and PCR amplification
Viral RNA was extracted from the clinical specimens using a
QIAamp Mini viral RNA Extraction Kit (Qiagen). The primers
used for RT-PCR are listed in Table 1. RT-PCR amplification
was performed using AccessQuickTM RT-PCR kit (Promega).
Conditions for RT-PCR amplification were: 45 min of reverse
transcription at 45uC; 5 min denaturation at 94uC; 35 cycles of
95uC for 40 sec, 53uC for 40 sec, 72uC for 40 sec; and then a final
elongation step of 72uC for 5 min. The second round amplifica-
tion was performed in 25 ml volumes, which contains 2.5 ml 10x
PCR reaction buffer, 1 ml 10 mM dNTP, 0.5 ml 10 mM each
primer, 0.5 ml Taq (TaKaRa), 1 ml of the first-round PCR
product, and 19 ml Nuclease-Free Water, under the same
conditions as the first-round PCR, except reverse transcription
step. The PCR products were examined by electrophoresis with a
3.0% agarose gel.
Virus Isolation
Clinical specimens (including throat swabs and rectal swabs)
were submitted for virus isolation. Samples were inoculated into
RD and human laryngeal carcinoma (Hep-2) cell cultures.
Cultures that exhibited a characteristic enterovirus CPE were
further evaluated by RT-PCR and sequencing.
Neutralization test
Laboratory methods for measuring EV71 neutralizing antibody
followed standard protocol for the neutralization test on microtiter
plates [17,18]. Serum specimens were serially diluted two-fold
(from 8 to 2048) and mixed with equal volume of EV71 (100
TCID50/50 ml) at 37uC for 60 min. The mixtures were incubated
in replicate microplate cultures of human embryo rhabdomyosar-
coma (RD) cells. Cytopathic effects (CPE) were read under an
inverted microscope after 2 to 7 days. Neutralizing antibody titer
was defined as the highest dilution of serum that prevented the
occurrence of CPE.
Detection of IgM anti-EV71
IgM anti-EV71 was detected using an IgM m-chain capture
enzyme-linked immunoabsorbant assay (ELISA) (Beijing Wantai
Biological Pharmacy Enterprise Co., Ltd., China) according to
manufacturer’s instruction. Briefly, 100 ml of dilution buffer were
added to microplate wells pre-coated with anti-human IgM m-
chain, then 10 ml of serum samples were added and mixed
tenderly, incubated at 37uC for 30 min, washed 5 times with
washing buffer. Then 50 ml of the antigen solution, prepared by
inactivating and fracturing of the cell free culture supernatant of
an EV71 isolate JS/52-3/06, was added followed by 50 mlo fa
horseradish peroxidase (HRP)-conjugated mouse anti-EV71
monoclonal antibody, mixed, incubated for 30 min and then
washed 5 times. 100 ml of TMB substrate was added then
incubated at 37uC for 15 min before adding 50 ml2 NH 2SO4 for
terminating the reaction. The optical density (OD) was read at a
wavelength of 450 nm with a reference filter of 620 nm. The
cutoff value was calculated as 0.1+ mean OD value of the negative
control. If the mean absorbance value of the negative control was
lower than 0.05, this was treated as 0.05. Levels of anti-EV71 IgM
was expressed in S/CO value, which was calculated as the ratio of
the OD value obtained with the test sample to the cutoff value
determined concurrently. A S/CO value not less than 1.0
indicated a positive result.
Statistical analysis
The detection rate was compared between groups used two-
sided Fishers exact test and 95% confidence intervals (CI) were
calculated with the use of SPSS program (v. 11.5).
Results
Table 2 compared the prevalence and mean levels of IgM anti-
EV71 in serum samples collected from 165 EV71 infected patients
at different times from 1 to 41 days after onset. The detection rate
of IgM reached to 90% (18/20) in samples collected on the first
day after onset, remained on this high level during the very early
acute phase before the forth days after onset, and then increased to
95% to 100% for more than one month. The mean sensitivity of
IgM test in the acute phase is 94.1% (95% CI: 90.2–96.8). The
dynamic of IgM antibody level during acute phase was in
consistent with the detection rate, as indicated by the S/CO
values.
Table 3 compared the occurrence of IgM anti-EV71 in serum
samples obtained from other enterovirus-infected patients or
control subjects. IgM anti-EV71 was detected in 19 of 155 samples
(12.3%) from CA16-infected patients which indicated the cross-
reaction and 0 of 12 samples from patients infected with other
enteroviruses. The mean S/CO value of the cross-reaction
Table 1. List of primers designed for the specific
amplification of EV71 and CA16.
Primer name Sequences(59-39) Position(nt)
1st set primer
EV71-F1 59-AGAGCATGATTGAGACACG -39 2607-2627
EV71-R1 59-RTCTTTCTCYTGYTTGTGTTC-39 3083-3063
2nd set primer
EV71-F2 59-CRGGRTTAGTTGGAGAGATAG-39 2686-2706
EV71-R2 59-CGCAGGTGACATGAATGG-39 3020-3003
1st set primer
CA16-F1 59-TGCAGACATGATTGACCAG-39 2457-2475
CA16-R1 59-TCCCTACTGTCCTAATGCTA-39 3163-3144
2nd set primer
CA16-F2 59-TGTGTTGAACCAYCACTCC-39 2649-2667
CA16-R2 59-TAGGTAAACAACTCGCATTT-39 2824-2805
doi:10.1371/journal.pone.0011388.t001
Anti EV71 IgM ELISA
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positive samples from EV71-infected patients (mean =10.867.3).
Among control subjects who were not infected by enteroviruses,
the false positive results were found in 19 of 1907 samples (1.0%)
from healthy children and 1 of 807 samples (0.12%) from healthy
adults and absent in samples from patients with other childhood
illnesses and the rheumatoid factor positive patients. The
specificity of the assay was 98.7% (2990/3029, 95% CI: 98.2–
99.1). Rheumatoid factor was not a confounder.
Discussion
Several countries in Asia have instituted surveillance to provide
early warning of outbreaks, which are largely depended on the
timely case reports with pathogenic diagnosis from community
clinics [19,20]. Traditional laboratory diagnosis for EV71 is by cell
culture followed by neutralization tests with serotype-specific
antisera [9]. However, it requires weeks to obtain results.
Consequently, molecular methods such as PCR have been
developed to detect EV71 [10–13]. Unfortunately, these methods
require expensive and specialized equipment and trained person-
nel, and can not be applied in most community clinics in
developing world. IgM assays based on enzyme immunological
techniques had been generally used for tens of years in most
community clinics in many developing countries. The in-house
IgM assays for diagnosis of acute EV71 infection had been
established for years. However, the performance of the assays on
early diagnosis of EV71 infected patients had not been fully
evaluated. The results in this study showed a 90% sensitivity in
patients who were in their first illness day, and similar sensitivity
remained till 4 days after onset. After then the sensitivity increased
to 95% to 100% for more than one month. Generally this
sensitivity satisfies most of the demands for clinical early diagnosis
as well as for early warning of outbreaks. The specificity of the
assay in non-HFMD children is 99.1% (95% CI: 98.6–99.4),
similar as the 99.9% specificity in healthy adults. It is noticed that
substantial proportion (11.4%, 95%CI: 7.0–17.2) of children
infected with other non-EV71 enteroviruses were positive by the
IgM anti-EV71 assay. This cross-reaction was supposed to be due
to the common epitopes among enteroviruses, and was mild as
suggested by the lower S/CO values and the lower occurrence
rate.
In conclusion, the data here presented show that the detection
of IgM anti-EV71 by ELISA affords a reliable, convenient, and
prompt diagnosis of EV71 infection. The whole assay takes 90 min
using readily available ELISA equipment, is easy to perform with
low cost, which made it suitable in clinical diagnosis as well as in
public health utility.
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Table 2. Sensitivity of IgM anti-EV71 test at Different Times After Symptomatic Onset.
Days after onset Tested No. Positive No, Rate (%) (95% CI) Mean S/CO (SD)
1 20 18 90.0 (68.3–98.8) 4.66 (4.79)
2 25 22 88.0 (68.8–97.5) 6.00 (5.86)
3,4 43 39 90.7 (77.9–97.4) 6.90 (4.63)
5,10 53 51 96.2 (87.0–99.5) 11.92 (5.98)
11,20 43 42 97.7 (87.7–99.9) 16.41 (6.05)
21–30 13 13 100.0 (83.2–100.0) 9.39 (6.17)
31–41 20 19 95.0 (78.9–99.9) 5.95 (4.37)
Total 221 208 94.1 (90.2–96.8) 9.78 (6.84)
doi:10.1371/journal.pone.0011388.t002
Table 3. Specificity and cross-reactivity of IgM anti-EV71 in control subjects.
Ctrl Subjects No. tested No. positive Specificity (%)(95%CI)
Enterovirus infected children 167 19 88.6 (82.8–93.0)
CA16 153 19 87.6 (81.3–92.4)
Other enteroviruses 12 0 100 (73.5–100)
Other Children 2035 19 99.1 (98.6–99.4)
Other infectious diseases 128 0 100 (97.2–100)
Healthy children 1907 19 2 99.0 (98.5–99.4)
Healthy adults 807 1 99.9 (99.3–100)
Rheumatoid factor (+) 20 0 100 (83.2–100)
doi:10.1371/journal.pone.0011388.t003
Anti EV71 IgM ELISA
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